aTyr Pharma Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 87.29. In total, the insiders bought 4 165 378 and sold 335 127 LIFE shares in the last 100 trades.

Insider Power

(Last 100 transactions)
87.29
Buy 4 165 378 Shares
Sell 335 127 Shares

Historical Insider Trades

Date Type Action Person Amount
May 31, 2024 Common Stock Buy Broadfoot Jill Marie 5 000
May 31, 2024 Common Stock Buy Shukla Sanjay 20 000
May 30, 2024 Common Stock Buy Coughlin Timothy 50 000
May 22, 2024 Stock Option (right to buy) Buy Clarke John K 24 000
May 22, 2024 Stock Option (right to buy) Buy Gross Jane A 24 000
May 22, 2024 Stock Option (right to buy) Buy Lucas Svetlana 24 000
May 22, 2024 Stock Option (right to buy) Buy Schimmel Paul 24 000
May 22, 2024 Stock Option (right to buy) Buy Zaknoen Sara 24 000
May 22, 2024 Stock Option (right to buy) Buy Coughlin Timothy 24 000
Feb 06, 2024 Common stock Sell Broadfoot Jill Marie 1 590
Feb 05, 2024 Common stock Buy Shukla Sanjay 10 375
Feb 05, 2024 Restricted Stock Unit Sell Shukla Sanjay 10 375
Feb 05, 2024 Common stock Buy Broadfoot Jill Marie 3 750
Feb 05, 2024 Restricted Stock Unit Sell Broadfoot Jill Marie 3 750
Feb 05, 2024 Common stock Buy Denyes Nancy 2 688
Feb 05, 2024 Restricted Stock Unit Sell Denyes Nancy 2 688
Jan 05, 2024 Employee Stock Option (right to buy) Buy Shukla Sanjay 600 000
Jan 05, 2024 Employee Stock Option (right to buy) Buy Broadfoot Jill Marie 150 000
Jan 05, 2024 Employee Stock Option (right to buy) Buy Denyes Nancy 150 000
Dec 12, 2023 Common Stock Buy Shukla Sanjay 12 000
Dec 11, 2023 Common Stock Buy Shukla Sanjay 3 000
Nov 13, 2023 Common Stock Buy Shukla Sanjay 13 578
Nov 10, 2023 Common Stock Buy Shukla Sanjay 1 422
Jul 28, 2023 Common Stock Buy Shukla Sanjay 15 000
May 17, 2023 Stock Option (right to buy) Buy Zaknoen Sara 12 000
Click to get the best stock tips daily for free!

About aTyr Pharma

aTyr Pharma aTyr Pharma, Inc., a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase II clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and ... LIFE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT